Glenmark Life Sciences Ltd

NSE : GLS

BSE: 543322

SECTOR : PHARMACEUTICALS

No data to show from BSE

52w high/low	₹799 / ₹587.55
P/E ratio	22.79
Dividend	2.57
ROE	20.19
ROCE	26.94
Face value	2
Book value	₹190.35Cr
Market capital	₹10,730.32Cr

Shareholding pattern

What is shareholding pattern? Who are shareholders?

Shareholding pattern represents the percentage of share ownership that different investors are holding in the company. A company can have multiple investors who invest in its shares. These are called as shareholders and there are two major categories of shareholders - promoters and public shareholders.

Promoters are typically the founders and public shareholders could be financial institutes like banks, insurance companies, domestic institutional investors, foreign institutional investors and common public.

Cash flow

What is a cash flow statement?

It is a financial statement that offers aggregate statistics on all cash inflows a business collects from its continuing activities and external sources of investment. It also includes all cash outflows over a specified time paying for company operations and investments.The main components of the CFS are cash from three areas: operating, investing, and financing activities...Read more

Balance Sheet

What is a balance sheet?

A balance sheet is a financial statement that records the assets, liabilities, and equity of a company at a certain point in time and provides a basis for estimating return rates and determining the capital structure. It offers a snapshot of what an entity owns and owes, as well as the sum that shareholders spend.The balance sheet complies with the following accounting equation in which assets on the one side, and liabilities plus shareholders' equity on the other, balance out:

Assets = Liabilities + Shareholder's Equity

This is used to conduct fundamental analysis or the estimation of financial ratios alongside other essential financial statements, such as income statement and statement of cash flows...Read more

Profit and loss

What is a profit and loss statement?

A profit and loss statement is a financial statement that represents the revenues, costs and expenses that the company has incurred during a quater or a fiscal year. It is also sometimes referred to as statement of profit and loss, income statement or statement of operations. This statement basically shows the investors and management whether the company has incurred profits or losses and in which areas.

Key Ratios

PE TTM

22.79

P/B

4.6

ROE

20.19

ROCE

26.94

Dividend yield

2.57%

EPS TTM

38.43

EBTIDA Growth

6.42

D/E

0.01

Sector PE

47.45

₹190.35Cr

Peer Comparison

Dividends

What are dividends?

Dividend, in financial terms, means a certain amount shared with shareholders of a company or a mutual fund on a regular basis – monthly, quarterly or annually. Read more

Bonuses

What are bonuses?

A bonus issue is an offer given to the existing shareholders of the company to subscribe for additional shares. Instead of increasing the dividend payout, the companies off... Read more

Company News

Sorry, we do not have any data here.

Sector News

Sorry, we do not have any data here.

About Glenmark Life Sciences Ltd

The company was incorporated as Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on 23 June 2011 at Pune and was granted the certificate of incorporation by the Registrar of Companies, Maharashtra at Pune ('RoC'). Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' pursuant to a special resolution passed by the shareholders of the Company on 25 July 2018 and a fresh certificate of incorporation dated 10 August 2018 was issued by the RoC. A shareholders' resolution was passed on 13 August 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited. The Company acquired API division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January 2019. The company is primarily engaged in the business of development,manufacture and marketing of Active Pharmaceutical Ingredients(APIs). The company's R&D facilities are located at Mahape,Ankleshwar and Dahej and manufacturing facilities are located at Ankleshwar,Dahej,Mohol and Kurkumbh. During the year 2018-19, the company allotted 4,50,090 Equity Shares of Rs.